Bedeutung des EU Spidia Projekts für Biobanken

Standardization and Improvement of Generic PreanalyticalTools and Procedures for In Vitro Diagnostics

11. Jahrestagung
Sektion Molekulare Diagnostik der DGKL

Tutzing, 10. May 2012

Dr. Uwe Oelmüller
QIAGEN GmbH (Koordinator)

Agenda

- **SPIDIA Project History and Goals**
- Results & Status
  - New Technologies & Tools
  - Pan-European Guidelines
  - Sample Quality Markers

Diagnostic Workflow
From Patients to Clinical Results



It is Real Problem

"Preanalytical errors still account for nearly 60%-70% of all problems occurring in laboratory diagnostics, most of them attributable to mishandling procedures during collection, handling, preparing or storing the specimens".

Lippi G. *et al.*. Preanalytical quality improvement: from dream to reality. Clin Chem Lab Med. 2011 Jul; 49(7):1113-26. Epub 2011 Apr 25.



Costs of ~ 347,000 € / year in an average German hospital caused by pre-analytical errors

Frost & Sullivan 2011 on behalf of BD

Project Main Goals

1. Pan-European guidelines (Molecular)
2. New tools & technologies
3. Sample quality biomarkers
4. Training and dissemination
5. Co-work with other international initiatives
    - NCI / OBBR, CLSI, EFCC etc.

SPIDIA Project Facts

Consortium	7 public research organizations 8 companies 1 standards organization (CEN)
Coordinator	QIAGEN GmbH
October 2008	Kick Off Meeting
Duration	4 years (6 months prolongation intended)
Budget	13 Mio €
EC Contribution	9 Mio €
Web page	www.spidia.eu
Newsletter	

Agenda

- SPIDIA Project Project History and Goals
- **Results & Status**
  - **New Technologies & Tools**
  - Pan-European Guidelines
  - Sample Quality Markers

New Tissue Collection & Stabilization

PAXgene Tissue

- > 1.500 compounds and mixtures screened (3 years)
- > 8.000 tissue samples processed to date

- Fixation & Stabilization (non-cross linking)
- Linked RNA, DNA, protein isolation procedures



Allows histomorphology and molecular testing from the same specimen

For Research Use Only

Histomorphology and IHC
Research Study - PFPE vs. FFPE

H&E Staining IDC of Breast

Estrogen Receptor a (clone 1D5) IDC of Breast

FFPE

PFPE



PFPE revealed preservation of morphology and antigenicity comparable to FFPE

Groelz D. *et al.*, unpublished data.

Cap M. *et al.,* PLoS ONE 6(11): e27704 (2011)

Viertler C. *et al.*, Journal of Molecular Diagnostics 2012, accepted for publication.

Mammacarcinoma Case

RNA Profiling – Cryo vs FFPE vs PFPE

TaqMan Array Gene Signature 96-Well Plate:
Human molecular mechanism of cancer



Viertler *et al*., Journal of Molecular Diagnostics 2012, accepted for publication).
Groelz *et al*., unpublished data

ccfNA Profiles in Whole Blood
What is missing?



- Studies for understanding fcDNA and ccfRNA profile stability / changes in whole blood and in plasma
- Development of ccfDNA and ccfRNA profile preservation technologies

EDTA blood was incubated for up to 6 days at room temperature. Blood fcDNA pattern stability was determined by separating the purified plasma DNA on a 2100 Agilent Bioanalyzer

Horlitz M. *et al.*, unpublished data

Ongoing Technology & Tools Developments for Other Sample Types

- **Fine Needle Aspirates**
  - Stabilization of morphology, antigenicity, DNA, RNA, proteome
- **Whole Blood**
  - Stabilization of cell morphology and biomolecule profiles
- **Swabs**
  - Stabilization and improved processing of respiratory and samples for molecular analysis
- **Stabilized Whole Blood**
  - Integrated automated sample-to-result workflows (cellular RNA, ncRNAs incl. miRNAs)

Agenda

- SPIDIA Project Project History and Goals
- **Results & Status**
  - New Technologies & Tools
  - **Pan-European Guidelines**
  - Sample Quality Markers

Evidence Based Guidelines

Examples Blood DNA & RNA, Plasma ccfDNA

- Phase 1 Trials - Laboratories used their workflows & tools
- Let by Prof. Pazzagli (Univ. Florence), supported by the EFCC
- Guidelines / Standards Concepts - CEN
- Phase 2 Trials – Laboratories use SPIDIA's optimized workflows
- Guidelines / Technical Reports Developments - CEN

SPIDIA Trials	No. of Participants (29 countries)	Participants who sent NA samples back	Percentage of NA samples sent back
Blood RNA	102	93	91 %
Blood DNA	130	121	93 %
Plasma DNA	67	62	93 %
Total	299	276	92 %

Blood DNA Trial 1 - Examples for Pre-analytical Workflow Variations

- **Blood storage time before DNA extraction**
  - 39 labs: ≤ 6 days
  - 60 labs: 6 – 10 days
  - 53 labs: ≥ 10 days
- **Blood storage temperature before DNA extraction**
  - 18 labs: -20 ˚C
  - 129 labs: +4 ˚C
  - 9 labs: ambient temp.
- **Isolated DNA storage before analysis**
  - 20 labs: -20 ˚C
  - 111 labs: +4 ˚C
  - 27 labs: ambient temp.

Pazzagli M. *et al.*, manuscript in preparation

DNA Length Variation – Pulse Field Gel Electrophoresis



195 kb
4.36 kb

- High molecular weight DNA integrity: degradation, fragmentation
- High variability among samples

Hartmann C. *et al.,* unpublished results
Pazzagli M. et al., manuscript in preparation

Impact of DNA quality on Immune T cell Repertoire Analysis (ImmunID Technologies)

V contribution for each J gene – Research Trial (ImmunID Technologies, France)



Ref. DNA from UNFI (DIV 54%)



Sample 38 (Poor quality) (DIV 32%)

- Lost of all long V–J rearrangements
- Lost of part of intermediate length rearrangements

L. Barraud et al. Unpublished data.

Pazzagli M. et al., manuscript in preparation

Individual Samples React Differently

Changes of Transcripts Profiles in Blood

Human EDTA Blood stored at Room Temperature over 3 days



IL-1β mRNA

Guenther K. et al.. AMP Poster (2005)

Learning from Blood RNA Ring Trial 1

- No pooling of different donors' blood
  - Accept that only sub-groups of ring trial participating laboratories get the same blood samples
- No usual blood collection bags
  - Use dedicated EDTA bags
- Immediate cooling of blood bags
  - Artificial gene induction and down regulation to be avoided
- Use of intracellular RNA markers
  - External markers will behave differently

Proficiency Testing for Preanalytical Workflows used for Blood RNA Analysis



Fig. 2. General workflow of the Exp B study.

K. Günther, F. Malentacchi, P. Verderio, S. Pizzamiglio, C. M. Ciniselli, A. Tichopad, M. Kubista, R. Wyrich, M. Pazzagli, S. Gelmini. Implementation of a proficiency testing for the assessment of the preanalytical phase of blood samples used for RNA based analysis. Clin Chim Acta. 2012 Apr 11;413(7-8):779-86.

Blood Sample Shipment - RNA Profile Changes

Stabilized vs. EDTA Blood



Box plots reflecting the mRNA expression of GAPDH (Panel A), IL1B (Panel B), IL8 (Panel C), and FOS (Panel D) measured in the three sample types REF, RNA A (PAXgene Blood RNA) and RNA B (EDTA). Each box indicates the 25th and 75th percentiles. The horizontal line inside the box indicates the median, and the whiskers indicate the extreme measured values. The dotted horizontal line indicates the median value of the REF samples (prior shipment) and serves for comparison.

Guenther K. et al.. Clin Chim Acta. 2012 Apr 11;413(7-8):779-86.

Agenda

- SPIDIA Project Project History and Goals
- **Results & Status**
  - New Technologies & Tools
  - Pan-european Guidelines
  - **Sample Quality Markers**

Blood RNA Quality Marker Discovery

- Quality markers measuring RNA up- & down-regulation
  - >150 micro arrays & RT-PCR studies (time course experiments)
  - 17 candidates (gene induction, gene down regulation, RNA degradation)
  - Technical assay validation
  - Next step: Performance validation within larger donor cohorts



Rian E. *et al.*, unpublished data

Diagnostic Workflow
From Patients to Clinical Results



Acknowledgement
SPIDIA Consortium Members

- QIAGEN GmbH - Coordinator
- Medical University of Graz *(Prof. K. Zatloukal)*
- University of Florence *(Prof. M. Pazzagli)*
- CIRMMP Florence, CERM *(Prof. I. Bertini)*
- TATAA Biocenter
- PreAnalytiX GmbH
- DIAGENIC ASA
- Aros Applied Biotechnology
- Dako Denmark
- ACIES
- Biotechnology Inst. of Czech Academy of Science *(Prof. M. Kubista)*
- European Committee for Standardization (CEN)
- ImmunID Technologies
- Erasmus Medical Center Rotterdam *(Prof. P. Riegman)*
- Technical University Munich *(Prof. H. Hoefler, Prof. K. Becker)*
- Fondazione IRCCS Istituto Nazionale dei Tumori *(Dr. P. Verderio)*

Scientific Advisory Board

- *Prof. François Rousseau* (Univ. Laval, Quebec. CanGeneTest Network)
- *Dr. Roberta M. Madej* (CLSI)

Project Ethics Committee

- *Dr. Anne Cambon-Thomsen* (CNRS, INSERM, Tolouse, France)
- *Dr. Ruth Chadwick* (ESRC Centre, Cardiff University, UK)

SPIDIA Consortium
Bi-Annual Meeting Berlin November 2011

SPIDIA

Thank you!

Questions ?